Home > Boards > US OTC > Biotechs >

VistaGen Therapeutics, Inc. (VTGN)

VTGN RSS Feed
Add VTGN Price Alert      Hide Sticky   Hide Intro
Moderator: whosjohngalt
Search This Board: 
Last Post: 5/5/2021 5:41:06 PM - Followers: 101 - Board type: Free - Posts Today: 0

VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. Our CNS portfolio includes three differentiated drug candidates, PH94B, PH10 and AV-101, each with a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications.

Company WebsiteVistaGen Therapeutics, Inc. (VTGN)                                                                                               Press ReleasesPress Releases :: VistaGen Therapeutics, Inc. (VTGN)

FinancialsAll SEC Filings :: VistaGen Therapeutics, Inc. (VTGN)                                                                                 Leadership TeamLeadership :: VistaGen Therapeutics, Inc. (VTGN)

Current Stock PriceQuote :: VistaGen Therapeutics, Inc. (VTGN)                                                                               

 

Pipeline

Our CNS pipeline includes three differentiated new generation CNS drug candidates with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of our drug candidates, PH94B, PH10 and AV-101, has a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications in large mental health and neurology markets.

PH94B Neuroactive Nasal Spray

PH94B is an innovative investigational synthetic neuroactive pherine nasal spray with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with benzodiazepines. PH94B’s rapid-onset mechanism of action is fundamentally different from benzodiazepines and all other FDA-approved anti-anxiety medications. Developed from proprietary compounds called pherines and administered at non-systemic microgram doses as an odorless nasal spray, PH94B binds to nasal chemosensory receptors which activate neural circuits in the limbic amygdala that suppress fear and anxiety. Following a highly statistically significant (p=0.002) Phase 2 study of PH94B in adults with social anxiety disorder (SAD), and a successful meeting with the U.S. Food and Drug Administration (FDA), we are currently preparing for pivotal Phase 3 development of PH94B for the acute treatment of anxiety in adults with SAD.

The FDA has granted Fast Track designation for development of PH94B for SAD, the first such designation ever granted by the FDA for a SAD drug candidate. In a manner analogous to a rescue inhaler used before an asthma attack, PH94B has potential to be used by a person with SAD before an anxiety-provoking stressor.

Based on the results of Phase 2 studies, PH94B has the potential to be the first FDA-approved acute (on-demand) treatment of anxiety for millions who suffer from SAD. In addition, PH94B has potential in postpartum anxiety, preoperative anxiety, PTSD, panic disorder, and generalized anxiety disorder.

PH10 Neuroactive Nasal Spray

PH10 is a synthetic investigational neuroactive pherine nasal spray with a novel, rapid-onset mechanism of action that is fundamentally different from all current treatments for depression. Developed from proprietary compounds called pherines and administered at microgram doses as an odorless nasal spray, PH10 binds to nasal chemosensory receptors which activate neural circuits in the brain that produce antidepressant effects. Specifically, a microgram level dose of PH10 (6.4 mcg) engages specific nasal chemosensory neurons (NCNs). NCNs activate olfactory bulb neurons (OBNs) on the base of the brain. OBNs send neural connections to neurons in the central limbic amygdala, the brain center where mood is regulated. Neurons in the limbic amygdala stimulate release of excitatory neurotransmitters (glutamate, norepinephrine) resulting in rapid-onset antidepressant effects. Systemic uptake and distribution are not required to produce rapid-onset antidepressant effects. In a small exploratory randomized, double-blind, placebo-controlled Phase 2A clinical study in major depressive disorder (MDD), at a 6.4 mcg dose, rapid-onset antidepressant effects were observed and sustained for 8 weeks (p=0.022), without psychological side effects or safety concerns associated with ketamine-based therapy.

AV-101, an Oral NMDAR Glycine Site Antagonist

AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA (N-methyl-D-aspartate) glutamate receptor modulators. The NMDA receptor is a pivotal receptor in the brain and abnormal NMDA function is associated with multiple CNS diseases and disorders, including MDD, epilepsy, levodopa-induced dyskinesia, neuropathic pain and many others. AV-101 is an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), which binds uniquely at the glycine site of the NMDA receptor and has potential to be a new treatment for multiple CNS indications involving NMDA receptors, each with high unmet need.

Recent discoveries from successful AV-101 preclinical studies demonstrate a multi-fold concentration increase in the brain of AV-101 prodrug, and, more importantly, of 7-Cl-KYNA, AV-101's active metabolite, when AV-101 is administered adjunctively with probenecid, a safe and well-known oral anion transport inhibitor used to treat gout. This data suggest that it may be possible to increase therapeutic concentrations and duration of 7-Cl-KYNA in the brain, and thus increase NMDAR antagonism in patients when AV-101 and probenecid are combined.

VistaGen Investor Contact
Mark McPartland
VistaGen Therapeutics
Phone: (650) 577-3606

EmailIR@vistagen.com
 

VTGN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VTGN News: Statement of Changes in Beneficial Ownership (4) 05/04/2021 04:40:15 PM
VTGN News: Current Report Filing (8-k) 05/04/2021 04:36:54 PM
VTGN News: VistaGen names new chief commercial officer 05/04/2021 08:24:38 AM
VTGN News: VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer 05/04/2021 08:00:00 AM
VTGN News: Amended Statement of Beneficial Ownership (sc 13d/a) 04/29/2021 10:17:38 AM
PostSubject
#4701   everyone settle down whosjohngalt 05/05/21 05:41:06 PM
#4700   another solid week going on here whosjohngalt 05/05/21 02:53:55 PM
#4699   appointment today whosjohngalt 05/04/21 02:52:07 PM
#4698   nice week whosjohngalt 04/30/21 07:49:30 PM
#4697   190k buy today at 2.54, that ain't no beanie baby. whosjohngalt 04/30/21 10:12:26 AM
#4696   nice bounce back whosjohngalt 04/28/21 04:40:35 PM
#4695   True, I think that is the timeline but Johnny_C 04/21/21 07:21:48 PM
#4694   I see whosjohngalt 04/21/21 09:20:19 AM
#4693   I am not sure if it is to Johnny_C 04/19/21 06:26:00 PM
#4692   sorry is that an insider type report? Don't whosjohngalt 04/19/21 04:20:56 PM
#4691   Interesting report from Jeffries. Johnny_C 04/19/21 11:44:39 AM
#4690   new fiscal year whosjohngalt 04/01/21 10:59:07 AM
#4689   I think oral ketamine is not going to Johnny_C 03/28/21 07:13:50 PM
#4688   not whosjohngalt 03/26/21 10:46:13 PM
#4687   I thought that the other year. The oral Richard2 03/26/21 07:41:53 PM
#4686   yup easily 12-24 months but I see this phase whosjohngalt 03/24/21 11:59:00 AM
#4685   Hopefully we here news phase 3 clincal trial Johnny_C 03/24/21 11:44:02 AM
#4684   short sellers love this ticker, hopefully we can kick whosjohngalt 03/23/21 04:54:45 PM
#4683   “ VistaGen’s Poster Presentation at the Anxiety and JohnLocke101 03/22/21 08:40:47 AM
#4682   Nabbed a big chunk this time at 212 JohnLocke101 03/18/21 03:10:27 PM
#4681   I’ll take more at 2.22 - thank you. JohnLocke101 03/18/21 01:14:25 PM
#4680   Continuing to build position as it dips to JohnLocke101 03/17/21 01:11:25 PM
#4679   Timing seems odd, I thought they had plenty Johnny_C 03/15/21 06:48:26 PM
#4678   Thanks. https://ih.advfn.com/stock-market/NASDAQ/vistagen-therapeutics-VTGN JohnLocke101 03/15/21 06:07:34 PM
#4677   S3 refreshed. I think they will always Johnny_C 03/15/21 05:34:38 PM
#4676   Thanks for the great find Fress! pzottkpz 03/12/21 08:58:57 PM
#4675   phase 3 whosjohngalt 03/12/21 08:02:19 PM
#4674   Took some more at 2.26 JohnLocke101 03/12/21 09:57:31 AM
#4673   Adding on the dips. JohnLocke101 03/12/21 08:10:04 AM
#4672   It certainly has the potential. I took a JohnLocke101 03/11/21 06:44:34 PM
#4671   game changing stuff whosjohngalt 03/11/21 06:24:36 PM
#4670   Nice little move on the back of the JohnLocke101 03/11/21 10:49:54 AM
#4669   ”VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of JohnLocke101 03/11/21 08:38:59 AM
#4668   seems we have good support whosjohngalt 03/09/21 11:40:00 AM
#4667   VTGN Institutional Shares have skyrocketed to 61% this Fress 03/03/21 05:44:19 AM
#4666   VTGN there is a bidding war behind the Fress 03/03/21 05:26:34 AM
#4665   The MM blocking crew trying too hard...watch what Fress 03/02/21 09:22:01 PM
#4664   $2.05-$2.20 looks ok! Haa Porterhouse10 03/02/21 06:31:55 PM
#4663   Invest in the dip...... this stock is under Fress 03/02/21 02:45:45 PM
#4661   I will say it one more time this Fress 02/26/21 03:25:41 PM
#4660   Anticipated Study Catalysts: Fress 02/26/21 05:10:30 AM
#4659   This last week VistaGen Therapeutics initiated by Jefferies Fress 02/26/21 05:03:03 AM
#4658   holding strong and Long john what shix they Fress 02/24/21 03:10:15 PM
#4657   Should break New Highs soon if you sold Fress 02/24/21 08:37:02 AM
#4656   VTGN Looking beyond the standard Fress 02/24/21 07:54:15 AM
#4655   Shawn Singh of VistaGen Therapeutics: 5 Ways That Fress 02/23/21 06:38:46 PM
#4654   added 55k on the dip thank you!!!! Fress 02/23/21 03:52:36 PM
#4653   Their were dozens & dozens of companies working Fress 02/23/21 01:51:08 PM
#4652   SOFTBANK IS SAID TO PLAN BILLIONS TO INVEST Fress 02/23/21 01:34:33 PM
#4651   1 in 3 adults are depressed or anxious Fress 02/23/21 08:16:19 AM
PostSubject
Consent Preferences